AstraZeneca Earnings Call: Oncology Strength, Pipeline Bets

AstraZeneca plc ((GB:AZN)) has held its Q1 earnings call. Read on for the main highlights of the call.

AstraZeneca’s latest earnings call struck an optimistic tone, blending solid top-line growth with standout oncology performance and a string of positive late-stage trial readouts. Management acknowledged near-term pressures from patent expiries, pricing reforms and heavier investment, but argued that a deep pipeline and a busy 2026 catalyst calendar position the group for sustained value creation.

Total Revenue and Profit Growth

AstraZeneca opened the quarter with 8% total revenue growth, underlining resilient demand across key franchises despite mixed biopharma trends. Core operating profit rose 12%, outpacing sales thanks to operating leverage, while core EPS increased 5% to $2.58, with the bottom line held back by a less favorable tax rate versus the prior year.

Strong Oncology Performance

Oncology remained the engine of the business, delivering 16% revenue growth to $6.8 billion and demonstrating broad-based strength across flagship brands. Tagrisso grew 5% to $1.8 billion, Imfinzi surged 30% with Imfinzi and Imjudo combined up 28%, Calquence advanced 17% to above $900 million, and Enhertu jumped 34%, annualizing as a roughly $5 billion brand on an alliance basis.

Biopharmaceutical Growth Areas

Within biopharma, Respiratory & Immunology provided a bright spot, with revenue up 7% to $2.3 billion on expanding biologic adoption. Fasenra climbed 11% to $483 million, driven by rapid emerging-market growth and strong uptake in China, while Breztri, Tezspire and Saphnelo delivered double-digit gains supported by new indications and broader use in severe disease.

Rare Disease Momentum and New Assets

Rare Disease posted a robust 15% revenue increase to $2.4 billion, underscoring the durability of this high-margin segment amid wider industry pricing pressures. Ultomiris grew 18% and Strensiq surged 43%, while positive Phase III data for efzimfotase alfa reinforced management’s confidence in a multibillion-dollar peak sales opportunity for this next-wave asset.

Pipeline and R&D Delivery

Management spotlighted four high-value Phase III wins early in 2026, including tozorakimab and efzimfotase alfa, as evidence of the pipeline’s productivity and future growth potential. The number of active clinical trials increased 10% and patient enrollment rose 30% year on year, reflecting stepped-up investment in cutting-edge platforms such as cell therapies and T-cell engagers.

High Core Gross Margin and Operating Leverage

Profitability remained a key strength, with a core gross margin of 83% in the quarter and guidance for stable to slightly higher margins over the full year. That robust margin backdrop, coupled with disciplined cost control in commercial operations, helped deliver operating leverage and faster growth in core operating profit than in revenue.

Solid Cash Generation and Capital Allocation

Operating cash flow reached $3.4 billion, only slightly below last year’s level when adjusted for a large one-off milestone in Q1 2025, demonstrating continued cash-generating power. CapEx came in at $600 million, funding multiyear manufacturing build-outs, while management reiterated its outlook for mid- to high-single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates.

Tozorakimab: Potential First-in-Class COPD Biologic

Tozorakimab emerged as a potential first-in-class biologic for COPD, with pivotal trials OBERON, TITANIA and MIRANDA showing statistically significant and clinically meaningful reductions in moderate-to-severe exacerbations. The drug also displayed a favorable tolerability profile, and management emphasized a sizable eligible patient population, with regulatory filings now being prepared.

Biopharmaceuticals Overall Decline and CVRM Headwinds

Despite pockets of growth, total biopharmaceutical revenue slipped 2% to $5.8 billion, highlighting structural pressures in some mature franchises. The cardiovascular, renal and metabolism unit saw a 6% revenue decline to $3.3 billion, reflecting loss-of-exclusivity dynamics and the impact of generic competition that is likely to build over coming periods.

Farxiga and China Pricing/VBP Impact

Farxiga revenue fell 3% to $2.2 billion as a phased loss-of-exclusivity profile and new U.S. generic entrants, which began in April, weighed on performance. In China, Farxiga and other key brands such as Lynparza and roxadustat saw growth capped by value-based pricing reforms, with the market posting only a modest 2% revenue increase.

Selective Clinical Readout Challenges

Not all clinical news was positive, as some readouts underscored the risks inherent in late-stage development and complex rare diseases. The HICKORY study of efzimfotase alfa in adolescents and adults failed to achieve statistical significance on its primary six-minute walk test endpoint, and the PROSPERO extension for tozorakimab did not reach significance for severe exacerbations in former smokers despite numerical benefits.

Program Discontinuation and Mixed Outcomes

The company also recorded a pipeline setback by discontinuing Ultomiris development in high-risk CSA-AKI patients after failing to demonstrate consistent efficacy across chronic kidney disease severities. Management framed the decision as a disciplined capital allocation move, freeing resources for higher-probability programs while acknowledging the disappointment in an area of significant unmet need.

Increased Spend and Cash Outflows

Core R&D expenses increased 8% and represented 23% of revenue in the quarter, with full-year R&D now expected at the upper end of the low-20s percentage range as pipeline activity accelerates. CapEx is projected to rise by about one-third in 2026 and milestone payments around $2.5 billion will add to near-term cash outflows, reflecting both growth investment and partnership commitments.

Net Debt Increase and Dividend-Driven Outflow

Net debt climbed by roughly $2.5 billion during the quarter, driven mainly by payment of the second interim dividend for FY2025, underscoring AstraZeneca’s ongoing capital returns alongside heavy investment. Core finance expenses are expected to increase this year as higher lease costs and lower interest income offset underlying earnings growth, adding a modest headwind below the operating line.

Regulatory/Commercial Timing and Trial Amendments

Trial amendments and schedule shifts introduced some timing uncertainty into the company’s already busy clinical calendar, illustrating the complexity of global development. Changes such as the TL07 adjustment for quality control system implementation and a six-month exposure extension for cliramitug may push certain readouts, potentially affecting the phasing of news flow and future launch windows.

Pricing & Access Uncertainty

Management also cautioned that evolving pricing and access regimes, including MFN- or VBP-style initiatives in key markets, could affect future launches and reimbursement trajectories. While AstraZeneca believes its innovative portfolio should support strong uptake over time, the team acknowledged that payor negotiations and new frameworks could introduce volatility in launch curves and peak-price assumptions.

Forward-Looking Guidance and Outlook

Looking ahead, AstraZeneca reaffirmed full-year guidance for mid- to high-single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates, with current FX trends expected to give a small boost to sales. The company plans to keep core R&D toward the upper end of its targeted range and ramp up capital spending, as management leans into a rich pipeline and manufacturing expansion despite higher finance costs and a rising net debt load.

AstraZeneca’s Q1 call painted a picture of a company leaning hard into innovation, using strong oncology and rare disease momentum to offset pressures in mature biopharma franchises. For investors, the near term may be shaped by patent cliffs, pricing reforms and rising cash demands, but management is clearly betting that its late-stage pipeline and upcoming 2026 catalysts will ultimately drive the next leg of growth.